Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Fox Chase Cancer Center Buckingham
mi
from
Furlong, PA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Fox Chase Cancer Center Buckingham
mi
from
Furlong, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Sentara Cancer Institute at Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Sentara Cancer Institute at Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Schiffler Cancer Center at Wheeling Hospital
mi
from
Wheeling, WV
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Schiffler Cancer Center at Wheeling Hospital
mi
from
Wheeling, WV
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Regional Cancer Center at Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Regional Cancer Center at Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  11/14/2015
Waukesha Memorial Hospital Regional Cancer Center
mi
from
Waukesha, WI
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 11/14/2015
Waukesha Memorial Hospital Regional Cancer Center
mi
from
Waukesha, WI
Click here to add this to my saved trials
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.
Status: Enrolling
Updated:  11/16/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.
Status: Enrolling
Updated: 11/16/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.
Status: Enrolling
Updated:  11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.
Status: Enrolling
Updated: 11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer
Status: Enrolling
Updated:  11/16/2015
Veterans Administration Puget Sound Health Care System
mi
from
Seattle, WA
Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer
Status: Enrolling
Updated: 11/16/2015
Veterans Administration Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer
Status: Enrolling
Updated:  11/16/2015
Schiffler Cancer Center
mi
from
Wheeling, WV
Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer
Status: Enrolling
Updated: 11/16/2015
Schiffler Cancer Center
mi
from
Wheeling, WV
Click here to add this to my saved trials
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Status: Enrolling
Updated:  11/16/2015
Radiation Oncology 174 Department of Veterans Affairs
mi
from
Seattle, WA
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Status: Enrolling
Updated: 11/16/2015
Radiation Oncology 174 Department of Veterans Affairs
mi
from
Seattle, WA
Click here to add this to my saved trials
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Status: Enrolling
Updated:  11/16/2015
Schiffler Cancer Center
mi
from
Wheeling, WV
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Status: Enrolling
Updated: 11/16/2015
Schiffler Cancer Center
mi
from
Wheeling, WV
Click here to add this to my saved trials
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated:  11/16/2015
Odyssey Healthcare of Conroe
mi
from
Conroe, TX
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated: 11/16/2015
Odyssey Healthcare of Conroe
mi
from
Conroe, TX
Click here to add this to my saved trials
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated:  11/16/2015
Odyssey Healthcare of Houston
mi
from
Houston, TX
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated: 11/16/2015
Odyssey Healthcare of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated:  11/16/2015
Houston Hospice and Palliative Care System
mi
from
Houston, TX
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated: 11/16/2015
Houston Hospice and Palliative Care System
mi
from
Houston, TX
Click here to add this to my saved trials
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated:  11/16/2015
Vitas Healthcare
mi
from
Houston, TX
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated: 11/16/2015
Vitas Healthcare
mi
from
Houston, TX
Click here to add this to my saved trials
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated:  11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Parenteral Hydration in Advanced Cancer Patients
Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial
Status: Enrolling
Updated: 11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
Sibley Memorial Hospital
mi
from
Washington,
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
Sibley Memorial Hospital
mi
from
Washington,
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
MedStar Union Memorial Hospital
mi
from
Baltimore, MD
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
MedStar Union Memorial Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
MedStar Good Samaritan Hospital Cancer Center
mi
from
Baltimore, MD
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
MedStar Good Samaritan Hospital Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
Carl R. Darnall Army Medical Center
mi
from
Fort Hood, TX
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
Carl R. Darnall Army Medical Center
mi
from
Fort Hood, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
San Antonio Army Medical Center
mi
from
Fort Sam Houston, TX
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
San Antonio Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
STOH Clinical Research
mi
from
San Antonio, TX
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
STOH Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
Madigan Army Medical Center - Tacoma
mi
from
Tacoma, WA
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
Madigan Army Medical Center - Tacoma
mi
from
Tacoma, WA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated:  11/16/2015
Landstuhl Regional Medical Center
mi
from
Landstuhl,
Vaccine Therapy in Treating Patients With Breast Cancer
Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients
Status: Enrolling
Updated: 11/16/2015
Landstuhl Regional Medical Center
mi
from
Landstuhl,
Click here to add this to my saved trials